Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Potential new uses of rifaximin are examined in a recent CID article by Adachi and DuPont. Rifaximin, a semisynthetic derivative of rifamycin, received FDA approval in May of 2004, for the treatment of traveler’s diarrhea in patients 12 years of age and older caused by non-invasive strains of E. coli.

Rifaximin For Gastrointestinal Disorders